Pfizer Inc. (NYSE:PFE) is one of the most active US stocks to buy right now. On April 28, Pfizer entered into settlement ...

Pfizer has reached agreements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla, regarding lawsuits filed in the U.S.

BridgeBio (BBIO) rose 6.6% after a court filing disclosed a settlement in a generic patent case over Pfizer's (PFE) Vyndamax ...

Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...

AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record net ...

Pfizer heads into earnings with a lower Goldman Sachs price target as investors weigh patent risks, Covid declines, and ...

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

Pfizer and President Donald Trump are partnering to launch a direct-to-consumer drug sales website called TrumpRx. As part of the deal, Pfizer will invest in U.S. manufacturing and receive a ...